{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:00:44Z","timestamp":1776445244324,"version":"3.51.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:00:00Z","timestamp":1687651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:00:00Z","timestamp":1687651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s12325-023-02575-1","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T06:01:18Z","timestamp":1687672878000},"page":"3804-3816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase\u00a01, Single- and Multiple-Dose Study"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct03073213","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Min","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HongYing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YiHui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZiPei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,25]]},"reference":[{"key":"2575_CR1","unstructured":"Global Psoriasis Atlas. https:\/\/globalpsoriasisatlas.org\/key-messages. Accessed 13 Feb 2022."},{"key":"2575_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1684\/ejd.2012.1802","volume":"22","author":"X Ding","year":"2012","unstructured":"Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22:663\u20137.","journal-title":"Eur J Dermatol"},{"key":"2575_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263\u201371.","journal-title":"Lancet"},{"key":"2575_CR4","doi-asserted-by":"publisher","first-page":"46381","DOI":"10.18632\/oncotarget.18453","volume":"8","author":"K Chen","year":"2017","unstructured":"Chen K, Wang G, Jin H, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget. 2017;8:46381\u20139.","journal-title":"Oncotarget"},{"key":"2575_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"2575_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","volume":"6","author":"AB Kimball","year":"2005","unstructured":"Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383\u201392.","journal-title":"Am J Clin Dermatol"},{"key":"2575_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2575_CR8","first-page":"667","volume":"52","author":"Committee on Psoriasis, Chinese Society of Dermatology","year":"2019","unstructured":"Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China. Chin J Dermatol. 2019;52:667\u2013710.","journal-title":"Chin J Dermatol"},{"key":"2575_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541\u201351.","journal-title":"Lancet"},{"key":"2575_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345\u201356.","journal-title":"N Engl J Med"},{"key":"2575_CR11","unstructured":"EPAR. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/taltz-epar-public-assessment-report_en.pdf. Accessed 12 May 2023."},{"key":"2575_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/jdv.13768","volume":"31","author":"K Callis Duffin","year":"2017","unstructured":"Callis Duffin K, Bagel J, Bukhalo M, et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017;31:107\u201313.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2575_CR13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/jcph.1268","volume":"58","author":"E Chigutsa","year":"2018","unstructured":"Chigutsa E, Velez de Mendizabal N, Chua L, et al. Exposure-response modeling to characterize the relationship between ixekizumab serum drug concentrations and efficacy responses at week 12 in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2018;58(11):1489\u2013500.","journal-title":"J Clin Pharmacol"},{"key":"2575_CR14","unstructured":"Choi S-L, Jackson K, Chigutsa E, et al. A longitudinal PKPD model describing the static Physician Global Assessment (sPGA) Response to ixekizumab in patients with moderate-to-severe plaque psoriasis. Poster Presentation. International Society of Pharmacometrics\u20147th American Conference on Pharmacometrics, Washington. 2016."},{"key":"2575_CR15","unstructured":"Velez de Mendizabal N, Chigutsa E, Heathman M, Choi S-L, Chua L, Friedrich S. A categorical time course PKPD model describing the effect of ixekizumab on improvement from baseline in Psoriasis Area and Severity Index (PASI) score in patients with moderate to severe plaque psoriasis. Poster presentation. PAGE. 2016."},{"issue":"1","key":"2575_CR16","doi-asserted-by":"publisher","first-page":"2160196","DOI":"10.1080\/09546634.2022.2160196","volume":"34","author":"A Reich","year":"2023","unstructured":"Reich A, Reed C, Schuster C, Robert C, Treuer T, Lubrano E. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016\u20132021. J Dermatolog Treat. 2023;34(1):2160196.","journal-title":"J Dermatolog Treat"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02575-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02575-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02575-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:17:08Z","timestamp":1692112628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02575-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,25]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2575"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02575-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,25]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}